In-vitro anticancer activity combination of eugenol and simple aromatic benzoate compounds against human colon HCT-116 cells and WiDr cells

Colon cancer is the third most common malignancy around the world. Surgery, chemotherapy, and radiotherapy are generally used to treat colon cancer, but no effective therapy for advanced colon carcinoma is available. The purpose of this research work is to evaluation of the anticancer activity of combination simple aromatic benzoate (SAB) compounds and eugenol (EU) against colon cancer cell line HCT 116. In this study cytotoxicity of SP and EU on HCT116 and WiDr cell was evaluated by MTT assay. Inhibitory action on HCT116 cell line in concentration range between 50 mg/ml to 3.125 mg/ml by using MTT assay. IC50 value single compounds of TFBA and Eu on HCT116 cell was 0.35 and 22.3 respectively. IC50 value TFBA and Eu on WiDr cell was 0.29 and 26.7 respectively by MTT assay. IC50 value combined compounds of EU-TFBA on HCT116 and WiDr cell was 20.7 and 20.1 respectively by MTT assay. From the performed assay, TFBA of these simple aromatics compounds shows greater activity on HCT116 and WiDr cell line and combined EU-TFBA shows greater activity on HCT116 and WiDr cell line than other combined EU-SAB, that mean TFBA and EU-TFBA can be used as anticancer activity.